Allurion Technologies announces publication of Allurion Program meta-analysis

Allurion Technologies announced the publication of a systematic review and meta-analysis evaluating the effectiveness and safety of the Allurion Program. The analysis reviewed studies conducted between 2016 and 2024 and included data from 11 observational studies comprising a total of 2,107 patients. The results of the meta-analysis demonstrated a mean weight reduction of 12.5% and significant reduction in body mass index, or BMI, of 4.75 kg/m2 at four months. Importantly, the analysis also confirmed the safety of the Allurion Balloon, with a rate of serious adverse events reported of just 0.90%. The study’s findings are further supported by the observed improvements in metabolic health parameters, particularly in HDL cholesterol, triglycerides, and glycemia, indicating the broad-reaching benefits of the Allurion Program beyond just weight reduction.